AMEBA Amoeba SA

Edison issues report on Amoéba (ALMIB)

Edison Investment Research Limited
Edison issues report on Amoéba (ALMIB)

21-Jun-2024 / 12:36 GMT/BST
The issuer is solely responsible for the content of this announcement.

 

London, UK, 21 Juni 2024

 

Edison issues report on Amoéba (ALMIB)

to view the full report.

All reports published by Edison are available to download free of charge from its website

Edison is authorised and regulated by the .

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

+44 (0)20 3077 5700

Connect with Edison on:

 

LinkedIn 

X  

YouTube 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1930811  21-Jun-2024 

fncls.ssp?fn=show_t_gif&application_id=1930811&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
21/06/2024

Underlying

AMEBAAmoeba SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Amoeba SA

Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba Partnership with Koppert signed

Amoéba has finalized a major five-year distribution agreement with Dutch biocontrol leader Koppert for its biofungicide Axpera, following a memorandum of understanding signed in December 2024. The deal grants Koppert exclusive rights across 18 European countries and the US, with a product launch expected in early 2026 under Koppert's brand. Production will occur at Amoéba's Chassieu site and via CDMO partners. The companies also plan to co-develop new biofungicide solutions. While financial term...

06/04/25 June 4, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba Unanimously positive EU vote on active substance as biocontrol

Amoéba received unanimous positive votes from all 27 EU Member States for its active substance to be used as a low-risk biocontrol. The vote followed a positive scientific opinion from EFSA in January 2025 and now paves the way for the European Commission to formalize the approval through an implementing regulation. The vote supports Amoéba's plans to commercialize its biocontrol product Axpera, with first EU sales expected by late 2025 or 2026, as the final product is already undergoing regulat...

05/22/25 May 22, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba Talks with Koppert extended

Amoéba announced that it continues its discussions with Dutch biocontrol leader Koppert to prepare for the commercial launch of Amoéba's biocontrol product Axpera. Initiated in December 2024, these talks have been extended to finalize contractual documentation following constructive discussions on market expectations and commercial strategies. Meanwhile, Axpera has received emergency market authorization in France for combating downy mildew in vines and exceptional authorization for use in sever...

05/13/25 May 13, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba Authorisation for large-scale greenhouse trials in the Netherla...

Amoéba has received an exceptional exemption in the Netherlands for large-scale greenhouse trials with its biocontrol product, Axpera, allowing the crops to be consumed. The authorisation could help validate Axpera's effectiveness under commercial conditions and potentially speed up the commercial rollout once formal EU approval has been obtained. We see strong potential in Amoéba's amoeba lysate in both biocontrol and cosmetics, hence reiterate our Buy rating with a € 1.7 TP.

05/07/25 May 7, 2025 1 EN
Thomas Vranken
  • Thomas Vranken
AMEBA AMOEBA SA

Amoéba Axpera obtains emergency market authorisation in France

Amoéba has received a 120-day emergency market authorisation from the French Ministry of Agriculture for its biocontrol product Axpera to combat downy mildew on grapevines in France. This approval allows large-scale field trials from mid-April to mid-August 2025, covering up to 250 hectares, supported by the French Wine and Vine Institute. The milestone represents another validation of Amoéba's innovative biocontrol application, and while significant sales are not yet expected in 2025, the early...

04/23/25 April 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch